Andrea Chirico1, Deborah Vizza2, Moira Valente2, Melania Lo Iacono2, Maria Rosita Campagna2, Tommaso Palombi1, Fabio Alivernini1, Fabio Lucidi1, Francesco Bruno3,4. 1. Department of Psychology of Development and Socialization Processes, Sapienza University of Rome, Rome, Italy. 2. Academy of Cognitive Behavioral Sciences of Calabria (ASCoC), Lamezia Terme, Italy. 3. Academy of Cognitive Behavioral Sciences of Calabria (ASCoC), Lamezia Terme, Italy. f.bruno@uniroma1.it. 4. Regional Neurogenetic Centre (CRN), Department of Primary Care, Azienda Sanitaria Provinciale Catanzaro, Viale A. Perugini, 88046, Lamezia Terme, CZ, Italy. f.bruno@uniroma1.it.
Abstract
PURPOSE: The fear of cancer recurrence (FCR) is one of the most reported problems by cancer survivors. A valid instrument to detect this issue could be useful to identify cancer survivors who are more vulnerable to developing FCR and related adverse outcomes (e.g., anxiety). The present study aimed to evaluate FCR in a sample of Italian breast cancer survivors using an Italian version of the 8-item Cancer Worry Scale (CWS) in order to establish a cut-off for the use in clinical settings. METHODS: The participants were 119 breast cancer survivors (mean age 47.7 years) at least 1 year after their primary treatment. An exploratory factor analysis (EFA) of CWS, internal reliability of CWS, concurrent and divergent validity using a bivariate correlation between the key measures of the study (i.e., FCR, anxiety, depression, fatigue, and self-efficacy), and ROC analysis of CWS were performed. RESULTS: Fit indices for the EFA were considered acceptable and showed a two-factor structure-labeled cancer worries and worries impact. The reliability of the two factors showed a Cronbach's alpha coefficient greater than 0.90. The CWS was positively related to anxiety, depression, fatigue, and negatively related to perceived self-efficacy. The best cut-off score was 24 versus 25, with a sensitivity of 74% and a specificity of 85%. CONCLUSIONS: The CWS is a valid questionnaire to assess FCR among breast cancer survivors. The present study provides an overview of the relationship between CWS and the adverse outcomes related to FCR and coping strategies adopted to face it.
PURPOSE: The fear of cancer recurrence (FCR) is one of the most reported problems by cancer survivors. A valid instrument to detect this issue could be useful to identify cancer survivors who are more vulnerable to developing FCR and related adverse outcomes (e.g., anxiety). The present study aimed to evaluate FCR in a sample of Italian breast cancer survivors using an Italian version of the 8-item Cancer Worry Scale (CWS) in order to establish a cut-off for the use in clinical settings. METHODS: The participants were 119 breast cancer survivors (mean age 47.7 years) at least 1 year after their primary treatment. An exploratory factor analysis (EFA) of CWS, internal reliability of CWS, concurrent and divergent validity using a bivariate correlation between the key measures of the study (i.e., FCR, anxiety, depression, fatigue, and self-efficacy), and ROC analysis of CWS were performed. RESULTS: Fit indices for the EFA were considered acceptable and showed a two-factor structure-labeled cancer worries and worries impact. The reliability of the two factors showed a Cronbach's alpha coefficient greater than 0.90. The CWS was positively related to anxiety, depression, fatigue, and negatively related to perceived self-efficacy. The best cut-off score was 24 versus 25, with a sensitivity of 74% and a specificity of 85%. CONCLUSIONS: The CWS is a valid questionnaire to assess FCR among breast cancer survivors. The present study provides an overview of the relationship between CWS and the adverse outcomes related to FCR and coping strategies adopted to face it.
Authors: Victoria L Champion; Celette Sugg Skinner; Usha Menon; Susan Rawl; R Brian Giesler; Patrick Monahan; Joanne Daggy Journal: J Health Psychol Date: 2004-11
Authors: Joanna E Fardell; Georden Jones; Allan Ben Smith; Sophie Lebel; Belinda Thewes; Daniel Costa; Kerry Tiller; Sébastien Simard; Andrea Feldstain; Sara Beattie; Megan McCallum; Phyllis Butow Journal: Psychooncology Date: 2017-08-18 Impact factor: 3.894
Authors: N Flanagan; S A Boyadjiev; J Harper; L Kyne; M Earley; R Watson; E W Jabs; M T Geraghty Journal: J Med Genet Date: 1998-09 Impact factor: 6.318
Authors: José A E Custers; Sanne W van den Berg; Hanneke W M van Laarhoven; Eveline M A Bleiker; Marieke F M Gielissen; Judith B Prins Journal: Cancer Nurs Date: 2014 Jan-Feb Impact factor: 2.592
Authors: Kirsten F L Douma; Neil K Aaronson; Hans F A Vasen; Miranda A Gerritsma; Chad M Gundy; Esther P A Janssen; Annette H J T Vriends; Annemieke Cats; Senno Verhoef; Eveline M A Bleiker Journal: Psychooncology Date: 2010-03 Impact factor: 3.894
Authors: Nina M Tauber; Mia S O'Toole; Andreas Dinkel; Jacqueline Galica; Gerry Humphris; Sophie Lebel; Christine Maheu; Gozde Ozakinci; Judith Prins; Louise Sharpe; Allan Ben Smith; Belinda Thewes; Sébastien Simard; Robert Zachariae Journal: J Clin Oncol Date: 2019-09-18 Impact factor: 44.544
Authors: Laura E Forrest; Rowan Forbes Shepherd; Erin Tutty; Angela Pearce; Ian Campbell; Lisa Devereux; Alison H Trainer; Paul A James; Mary-Anne Young Journal: J Pers Med Date: 2022-07-07